Skip to content

Pessaries in mulitple pregnancy as a prevention of preterm birth

Pessaries in mulitple pregnancy as a prevention of preterm birth - ProTwin

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON33360
Enrollment
660
Registered
2009-09-15
Start date
2009-10-01
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple pregnancy preterm birth

Interventions

Eligible women will be randomly allocated to receive either a cervical pessary or no intervention. The cervical pessary will be placed in situ at 16 to 20 weeks, and will stay in situ up to 36 weeks

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: All women presenting with a multiple pregnancy (monochorionic and bichorionic) between 12 and 20 weeks of gestation are eligible for the study

Exclusion criteria

Exclusion criteria: Women with multiple pregnancies in which at least one of the fetus(es) has major congenital anomalies known at study entry will not be included

Design outcomes

Primary

MeasureTime frame
The main outcome parameter is the composite morbidity rate of children in the two groups. This composite morbidity rate contains the following variables: severe Respiratory Distress Syndrome (RDS), Broncho Pulmonal Dysplasia (BPD), Intraventricular Haemorrhage II B or worse, Necrotizing Enterocolitis (NEC), proven sepsis and death before discharge from the nursery (6). They will be measured until 6 weeks after the date of delivery.

Secondary

MeasureTime frame
Secondary outcome measures are time to delivery, preterm birth rate before 32 and 37 weeks, days of admission in neonatal intensive care unit, maternal morbidity, maternal admission days for preterm labour and costs. At present, a longer follow-up is not planned.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)